GM-CSF Gene therapy using adenoviral vector in hamster pancreatic cancer

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 7, Issue 3, 2000, Pages 306-311

  Ogawa, Takahiro ^a,b   Kusumoto, Masahiro ^a   Mizumoto, Kazuhiro ^a   Sato, Norihiro ^a   Nagai, Eishi ^a   Ikubo, Akashi ^a,c   Aoki, Yasuaki ^a,c   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Shimonoseki City Hospital   (Japan)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Gene therapy; GM CSF gene; Pancreatic cancer; Vaccine

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADENOVIRUS; ANIMAL; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HAMSTER; METHODOLOGY; PANCREAS TUMOR; SECRETION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VACCINATION;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VACCINATION;

EID: 0033642883     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005340070053     Document Type: Article

References (24)

1. Ogawa T, Makino T, Kosahara K, Koga A, Nakayama F (1992) Promoting effects of both dietary cholesterol and cholestyramine on pancreatic carcinogcnesis initiated by N-nitrosobis(2-oxopropyl)amine in Syrian golden hamsters. Carcinogenesis 13: 2047-2052
2. Ogawa T, Makino T, Hirose N, Sugano M (1994) Lack of influence of low blood cholesterol levels on pancreatic carcinogenesis after initiation with N-nitrosobis(2-oxopropyl)amine in Syrian golden hamsters. Carcinogenesis 15:1663-1666
3. Suehara N, Mizumoto K, Kusumoto M, Niiyama H, Ogawa T, Yamaguchi K, Yokohata K, Tanaka M (1998) Telomerase activity detected in pancreatic juice 19 months before a tumor is detected in a patient with pancreatic cancer. Am J Gastroenterol 93:1967-1971
4. Suehara N, Mizumoto K, Muta T, Tominaga Y, Shimura H, Kitajima S, Hamasaki N, Tsuneyoshi M, Tanaka M (1997) Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states. Clin Cancer Res 3:993-998
5. Mizumoto K, Suehara N, Muta T, Kitajima S, Hamasaki NT, Shimura H, Tanaka M (1996) Semi-quantitative analysis of telomerase in pancreatic ductal adenocarcinoma. J Gastroenterol 31:894-897
6. Abdel-Wahb Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HF (1997) A phase 1 clinical trial of immunotherapy with interferon-gammma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 80:401-412
7. Ross G, Erickson R, Knorr D, Motulsky AG, Parkman R, Samulski J, Straus SE, Smith BR (1996) Gene therapy in the United States: a 5-year status report. Hum Gene Ther 7:1781-1790
8. Nagai E, Ogawa T, Kielian T, Ikubo A, Suzuki T (1998) Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice. Cancer Immunol Immunother 47:72-80
9. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
10. Metcalf D (1985) The granulocyte-macrophage colony stimulating factor. Science 229:16-22
11. Chen GH, Curtis JL, Mody CH, Christensen PJ, Armstrong LR, Toews GB (1994) Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J Immunol 152:724-734
12. Bernasconi S, Matteucci C, Sironi M, Conni M, Colotta F, Mosca M, Colombo N, Bonazzi C, Landoni F, Corbetta G (1995) Effects of granulocyte-monocyte colony-stimulating-factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int J Cancer 60:300-307
13. Clary BM, Coveney EC, Blazer DG, Philip R, Philip M, Morse M, Gilboa E, Lyerly HK (1996) Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Surgery 120:174-181
14. rd, Morse M, Gilboa E, Lyerly HK (1997) Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Cancer Gene Ther 4:97-104
15. Kimura M, Tagawa M, Takenaga K (1998) Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: a potentiality for cancer gene therapy. Cancer Lett 128:47-53
16. Kimura M, Tagawa M, Yoshida Y, Takenouchi T, Takenaga K, Azuma K, Yamaguchi T, Saisho H, Sakiyama S (1998) Impaired in vivo tumor growth of human pancreatic carcinoma cells transduced with GM-CSF gene. Anticancer Res 18:165-170
17. Mori T, Tsutsumi M, Noguchi O, Horiguchi K, Hohnoki K, Okita S, Suzuki F, Konishi Y (1994) Characterization of three cloned cell lines from a N-nitrosobis(2-hydroxypropyl)amine-induced transplantable hamster pancreatic ductal adenocarcinoma. Int Pancreatol 16:171-177
18. Okita S, Tsutsumi M, Onji M, Konishi Y (1995) p53 mutation without allelic loss and absence of mdm-2 amplication in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters. Mol Carcinogenesis 13:266-271
19. Egawa S, Tsutsumi M, Konisi Y, Kobari M, Matsuno S, Nagasaki K, Futami H, Yamaguchi K (1995) The role of angiogenesis in the tumor growth of Syrian hamster pancreatic cancer cell line HPD-NR. Gastroenterology 108:1526-1533
20. Konishi Y, Mizumoto K, Kitazawa S, Tsujiuchi T, Tsutsumi M, Kamano T (1990) Early ductal lesions of pancreatic carcinogenesis in animals and human. Int J Pancreatol 7:83-89
21. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H (1995) Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 121:587-592
22. Caracciolo D, Shirsat N, Wong GG, Lange B, Clark S, Rivera G (1987) Recombinant human macrophage colony-stimulating factor (M-CSF) requires subliminal concentrations of granulocyte/macrophage (GM)-CSF for optimal stimulation of human macrophage colony formation in vitro. J Exp Med 166:1851-1860
23. Mazur EM, Cohen JL, Wong GG, Clark SC (1987) Modest stimulatory effect of recombinant human GM-CSF on colony growth from peripheral blood human megakaryocyte progenitor cells. Exp Hematol 15:1128-1133
24. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H (1995) Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56:1828-1833